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1. Introduction
Anemia is a common complication in hemodialysis (HD) patients, mainly due to the insuffi‐
cient production of erythropoietin (EPO) by the failing kidneys [1]. Anemia itself can worsens
cardiac function, cognitive function, exercise capacity and quality of life, and it has been
independently associated with increased mortality and progression of renal disease [2, 3]. A
successful management of anemia is, therefore, crucial, as it may improve clinical outcome.
The introduction of recombinant human EPO (rhEPO) therapy to treat anemia of chronic
kidney disease (CKD) patients reduced anemia, improving patients’ quality of life [3]. There
is, however, a marked variability in the response to this therapy and 5-10% of patients develop
resistance to rhEPO therapy [4]. Resistance to rhEPO therapy has been associated to inflam‐
mation, oxidative stress and “functional” iron deficiency, as major causes.
EPO presents also an important protective role in other tissues, outside of the erythropoietic
system. Actually, a biological response to EPO and the expression of EPO receptors, have been
observed in many different cells, namely, in endothelial, neural and cardiac cells. However,
HD patients requiring high rhEPO doses present an increased risk of death [5]. Recently,
randomized controlled trials showed no benefit, or even increased risk of mortality and/or
cardiovascular complications, in HD patients with hemoglobin (Hb) concentration higher than
the target levels [6].
In this book chapter, a review of the etiological mechanisms associated with the development
of EPO resistant anemia, in HD patients, will be performed. We also intend to review also the
risk-benefits associated with high rhEPO doses used to achieve the target Hb levels.
© 2013 Ribeiro et al.; licensee InTech. This is an open access article distributed under the terms of the Creative
Commons Attribution License (http://creativecommons.org/licenses/by/3.0), which permits unrestricted use,
distribution, and reproduction in any medium, provided the original work is properly cited.
2. Anemia of chronic kidney disease
CKD is a pathological condition that results from a gradual, permanent loss of kidney function
over time, usually, months to years. CKD can result from primary diseases of the kidneys.
However, diabetic nephropathy and hypertension have been considered as the main causes
of CKD [1]. Anemia is a common complication of CKD that develops early in the course of the
disease increasing its frequency with the decline of renal function. The incidence of anemia is
less than 2 % in CKD stages 1 and 2, about 5% in CKD stage 3, 44% in CKD stage 4 and more
than 70% in the end-stage renal disease (ESRD) [7]. This condition is associated with a
decreased quality of life [3], increased hospitalization [2, 8], cardiovascular complications -
angina, left ventricular hypertrophy (LVH) and chronic heart failure – and mortality [9-12].
The European Best Practice Guidelines for the management of anemia in patients with CKD
recommends that a diagnosis of anemia in these patients should be considered when Hb
concentration falls below 11.5 g/dL in women, 13.5 g/dL in adult men and 12.0 g/dL in men
older than age 70 [13].
The anemia of these patients is, mainly, due to decreased kidney´s secretion of EPO. In CKD
patients there is a failure in increasing the EPO levels in response to hypoxia, as occurs in others
types of anemia. These patients present an EPO deficiency, rather than an absolute lack, as
EPO remains detectable even in the most advanced stages of CKD [14]. However, other factors
contribute to the anemia in these patients, as reduced red blood cell (RBC) life span, iron
deficiency, uremic toxins, HD procedure, blood loss and inflammation.
3. Erythropoiesis-stimulating agents
The correction of anemia in CKD patients needs pharmaceutical intervention with erythro‐
poiesis-stimulating agents (ESAs). An intravenous (i.v.) iron supplementation, as adjuvant
therapy, should be administrated to prevent iron deficiency and minimize the dose of ESA
needed to achieve the target-range of Hb levels [4, 13]. However, recently, some concerns about
this treatment of the anemia were raised and questioned in several studies, namely, the need
to define Hb targets, safety, benefits and costs of ESA treatments.
3.1. Pharmacology of erythropoiesis- stimulating agents
The introduction of ESAs revolutionized the treatment of anemia in CKD patients. After
cloning of the EPO gene, the recombinant human technology allowed the production of ESAs
that present the physiological role of EPO. Epoetin beta was the first ESA to be used. It was
presented in 1987 [15] and approved by the Food and Drug Administration (FDA) in 1989.
Since then, other ESAs appeared, with similar actions, differing in their half-life. Consequently,
they were divided in “short-acting” and “long-acting” ESAs (Table 1). The frequency of
administration and route of administration (usually, the intravenous (i.v.) administration is
more convenient for HD patients) is, therefore, conditioned by their half-life.
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In humans, it seems that the rhEPO treatment increases Hb concentration, and, thus, arterial
oxygen content, by increasing red cell volume and depressing plasma volume, probably
through a mechanism involving the reduction of the renin–angiotensin–aldosterone axis
activity [16].
The mechanisms for ESAs elimination are not well elucidated, and several hypotheses have
been considered [17, 18]:
• ESAs are primarily cleared by a hepatic pathway;
• Clearance of ESAs occurs through the kidneys;
• ESAs may be cleared via EPO receptor-mediated endocytosis and subsequent intracellular
degradation.
However, other mechanisms, not yet elucidated can be responsible for ESAs elimination.
ESA
Approval
Characteristics Half-life FrequencyadministrationFDA EMA
Short-acting
Epoetin beta 1989 Identical a.a. and carbohydratecomposition to EPO
i.v. 4 - 12 h
s.c. 12 – 28 h 3 times/week
Epoetin alpha 1989 1989 Identical a.a. and carbohydratecomposition to EPO
i.v. ≈ 5h
s.c. ≈ 24h 3 times/week
Epoetin zeta
(biosimilar medicine) 2007
Identical a.a. and carbohydrate
composition to EPO
i.v. ≈ 5h
s.c. ≈ 24h 3 times/week
Epoetin theta
(biosimilar medicine) 2009
Identical a.a. and carbohydrate
composition to EPO
i.v.≈ 4h
s.c. ≈ 34h 3 times/week
Long-acting
Darbopoetin alpha 2001 2001
2 additional N-linked
carbohydrate chains compared
to EPO
i.v. 21 hours
s.c. 73 hours once/week
Methoxy
polyethylene glycol-
epoetin beta
2007 2007
continuous
erythropoietin receptor
activator
i.v. 134 hours
s.c. 139 hours once/month
Peginesatide 2012
PEGylated, homodimeric
peptide with no sequence
homology to rhEPO
once/month
Abbreviations: FDA – Food and Drug Administration; EMA – European Medicines Agency; a.a. – amino acid; i.v. –
intravenous; s.c. – subcutaneous. rhEPO – recombinant human erythropoietin. Adapted from Food and Drug Adminis‐
tration (2012) [19], European Medecines Agency (2012) [20] and Green et al. (2012) [21].
Table 1. Erythropoiesis – stimulating agents.
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3.2. Non-hematopoietic actions of erythropoietin and erythropoiesis- stimulating agents
ESAs are designed to treat anemia, but recent evidences points to other non-hematopoietic
actions of EPO and ESAs [22]. Several pleiotropic effects have been attributed to EPO, such as
cytoprotective, antiapoptotic, anti-inflammatory and angiogenic capacities.
The erythropoietic and non-erythropoietic effects of EPO appear to result from the existence
of two different receptors with different affinities for EPO [23].
In erythroid cells, picomolar concentrations of EPO bind to the EPOR homodimers, whereas
on other cells and tissues EPO binds to an heterodimer receptor, constituted by EPOR and
CD131 (beta common receptor – βcR), and, high local EPO concentrations are needed to exert
its action [23-25]. The EPO variants, including asialo-EPO, carbamylated EPO (CEPO) or
carbamylated darbopoetin alpha (C-darbe), that present the protective effects of EPO in non-
haematopoietic tissues, but no hematopoietic activity [26-28], suggested the presence of two
types of receptors. EPOR are present in several cells and tissues, as brain (neurons, astrocytes,
and microglia) [29, 30], kidney [31], female reproductive system [32], vascular endothelial cells
[33], cardiomyocytes [34], lymphocytes and monocytes [35], among others.
Some of the non-hematopoietic effects of EPO are summarized:
• Cardioprotection: several studies showed that ESAs promote cardioprotection through the
inhibition of cardiomyocyte apoptosis, reduction of inflammation and oxidative stress, and
induction of angiogenesis [22-24, 34, 36].
• Anti-inflammatory properties: EPO and its derivates reduce the production of pro-inflam‐
matory cytokines, such as TNF-α, IL-6 and IL-1β, and NO (nitric oxide) via inducible NO
synthase (iNOS) through the inhibition of NF-κB pathway [23, 24, 37].
• Neuroprotection: EPO seems to be important for the neural development, as it stimulates
the differentiation of neural progenitor cells [29], but it also promotes angiogenesis and
reduces inflammation, oxidative stress and neuronal apoptosis in some conditions, as
hypoxia-ischemia (HI), stroke and neurotoxicity of glutamate [22-24, 29].
• Angiogenesis: EPO increases the number of functionally active endothelial progenitor cells
(EPCs), enhancing angiogenesis, and seems to be dependent on functional endothelial NO
synthase (eNOS) [24, 38]. EPO plays an important role in uterine angiogenesis, through
EPOR expressed by endometrial vascular endothelial cells [33].
• Immunomodulation: EPO may have effects on dendritic cells [potent antigen presenting
cells (APCs) that possess the ability to stimulate naïve T cells], presenting effects in innate
immunity [39].
• Renoprotection: several studies on acute kidney injury reported that a single dose of
rHuEPO reduces kidney dysfunction through an antiapoptotic mechanism, and increased
NO production, but only in intact vessels [31]. However, it appears that this renoprotection
is achieved only with low doses of EPO, non-hematopoietic doses, as high EPO doses cause
an increase in hematocrit that is accompanied with changes in hemorheology, activation of
thrombocytes and increased platelet adhesion to injured endothelium [31].
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3.3. Benefits of erythropoiesis-stimulating agents
ESAs have beneficial effects by correcting anemia and their associated symptons (fatigue,
dizziness, shortness of breath, among others), improving the quality of life of these patients
[40-42]. ESAs also reduce the need for transfusions, thereby reducing transfusion reactions
(immunological sensitization), transmission of infectious agents and iron overload [43].
The anemia of CKD is associated with cardiovascular complications, due to increasing blood
pressure and LVH. Indeed, LVH is present in many patients with CKD, even in the earlier
stages of the disease (75% of patients who start HD have LVH) and may lead to heart failure,
cardiac arrhythmia or both, that are considered as major causes of cardiac-related deaths in
this population [44, 45]. LVH is a physiological adaption that results from long-term increase
of myocardial work, from high-pressure or volume overload, which can lead to major cardiac
events. Volume overload can result from anemia, as hypoxia and the decreased blood viscosity
contribute to decrease peripheral resistance, and from increased venous return, both of which
increase cardiac output [44, 46]. LVH is also a risk factor for the development of uremic
cardiomyopathy, which is defined as congestive heart failure due to a primary disorder of the
heart muscle in uremic patients, and is characterized by profound systolic dysfunction and
cardiac fibrosis; however, increased sympathetic activity in response to anemia also appears
to be a factor for this condition [47, 48].
Several studies report the synergy between anemia and LVH and that the use of ESAs for
anemia correction (Hb target of approximately 11 g/dL) is associated with an improvement in
heart failure symptoms and with a reduction in LVH [45, 49].
The effects of ESAs on the progression of renal function are controversial. Some studies
demonstrated that following ESA initiation renal function declines at a slower rate and delays
the dialysis initiation in pre-dialysis patients [50-52], while other studies reported that ESAs
do not significantly slow renal function decline [53, 54].
3.4. Risks associated with erythropoiesis-stimulating agents
As referred, ESAs have several benefits beyond the treatment of anemia; however, its admin‐
istration seems to associate some risks. Cardiovascular and thromboembolic events have been
described. Some of the protective effects of EPO and ESAs, as described above, occurs upon
the activation of the heterodimeric EPOR; however, as the affinity of EPO for this receptor is
low, higher doses of EPO are needed to reach these effects.
One of the most described effects of ESAs is hypertension. Several mechanisms can explain
the rise in blood pressure (BP) mediated by ESAs. Renal anemia is a factor predisposing to
increase BP, due to the increased sympathetic activity and impaired NO availability [55]. ESAs
impair the balance between vasodilating and vasoconstrictor factors, since it induces the
production of vasoconstrictors as endothelin-1 (ET-1), thromboxane (TXB2) and prostaglandin
2α (PGF2α), and reduces the production of the vasodilatory prostacyclin (PGI2) [56, 57].
Chronic treatment with ESAs appears to impair the vasodilatory capacity of endothelial NO,
through an increase in the asymmetrical dimethylarginine (ADMA), an inhibitor of eNOS [57].
ESAs seem to induce hypersensitivity to angiotensin II, a recognized vasoconstrictor [56, 57].
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An increase in noradrenaline concentration and hypersensitivity - a vasoactive substance -
may contribute also to hypertension during ESA therapy [56, 57].
Treatment with ESAs is associated with an increase in the incidence of thrombotic events [58].
EPO has the capacity of stimulating thrombopoiesis, increasing platelet count; however, EPO
also increases platelet reactivity (especially on the newly synthesized ones) promoting a
prothrombic effect [59]. Some other hemostatic disturbances have been described, as an
increased expression in E selectin, P selectin, von Willebrand factor and plasminogen activator
inhibitor-1, which may favor bleeding episodes, and increase the risk of thrombosis and
thromboembolism, as occlusion of the vascular access [57].
An uncommon but serious complication associated with ESAs administration is pure red blood
cell aplasia, an immunogenic side effect that results from the production of antiEPO antibodies
induced by ESAs administration [60-62]. Indeed, the method used to produce ESAs may not
eliminate impurities or aggregated protein that may trigger the immune response in patients
[62]. Immunoprecipitation assays have shown that antiEPO antibodies are directed against the
protein moiety of the molecule [61].
ESAs are also indicated in the treatment of symptomatic anemia in adult cancer patients
with non-myeloid malignancies receiving chemotherapy. However, some evidences point
that these agents can accelerate tumor growth, but data are controversial.  High doses of
EPO  can  stimulate  endothelial  and  vascular  smooth  muscle  cell  proliferation  and  pro‐
mote angiogenesis.  The antiapoptotic pleiotropic effect of EPO can also contribute to tu‐
mor progression [57, 63].
4. Resistance to erythropoieses-stimulating agents
Although the majority of CKD patients respond adequately to ESAs, 10% of these patients
develops resistance to this therapy [4]. According to the European best practice guidelines for
the management of anemia in patients with chronic renal failure [13] resistance to ESAs is
defined as a failure to achieve target Hb levels (11– 12 g/dl) with doses lower than 300 IU/kg/
week of epoetin or 1.5 μg/kg/ week of darbopoietin-α. For the National Kidney Foundation
Disease Outcomes Quality Initiative (NKF KDOQI) guidelines [4], hyporesponsiveness to
ESAs therapy is defined by, at least, one of these situations: a significant increase in the ESA
dose required to maintain a certain Hb level, a significant decrease in Hb level at a constant
ESA dose or a failure to increase the Hb level to higher values than 11 g/dL, despite the
administration of an ESA dose equivalent to epoetin higher than 500 IU/kg/week.
ESAs resistance is associated with poor outcome, increasing the risk of mortality [5, 64, 65].
Hyporesponsiveness to ESAs therapy can have many underlying causes. The most common
causes are iron deficiency (absolute or functional), and inflammation.
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4.1. Iron deficiency
Iron-restricted erythropoiesis is frequent in CKD patients and is due to absolute or functional
iron deficiency. The latter seems to be the most common cause of hyporesponsiveness to ESAs
in HD patients [66, 67]. About 25-37% of CKD patients with anemia present with iron deficiency
[66]. Iron therapy is recommended, and i.v. iron supplementation is more effective than oral
supplementation in HD patients [67]. It is important to distinguish between absolute and
functional iron deficiency. Indeed, there is a controversy about iron supplementation when
transferring saturation is lower than 20% and ferritin is higher than 500ng/mL (functional
deficiency) [67, 68]. In this situation, probably associated with an inflammatory response, an
excess of iron can be potentially harmful to these patients.
4.2. Chronic blood loss
Blood loss is frequent in patients undergoing HD and could be a cause to an inadequate ESA
response. This condition should always be suspected in several conditions, namely, in patients
who need a higher dose of ESA to maintain a stable Hb concentration, in patients whose Hb
concentration is falling, and in patients who fail to increase iron stores, even after i.v. iron
supplementation [13].
4.3. Inflammation
The anemia of CKD is often referred as an inflammatory anemia. Indeed, inflammation is a
common feature in CKD patients, mainly, in those under HD. Inflammation is recognized as
one cause to hyporesponsiveness to ESA therapy, and several studies reported an association
between high levels of inflammatory markers and ESA resistance in CKD patients [5, 69-72].
Usually, HD patients present with high levels of inflammatory markers, namely, IL-6, CRP,
TNF-α, INF-γ, and with lower serum levels of albumin [69-71].
A week response to ESA also appears to be associated with enhanced T cell capacity to express
IFN-γ, TNF-α, IL-10, and IL-13 [70, 73]. Costa et al. [71] also reported a significant rise in
neutrophil count in non-responder patients. They also found positive correlations between
CRP and elastase and between elastase and rhEPO doses, suggesting that elastase, a neutrophil
protease released by degranulation, could be a good marker of resistance to rhEPO therapy in
HD patients under hemodialysis. Inflammation contributes to anemia through several ways:
• suppression of erythropoiesis: directly, by the inhibitory effects of pro-inflammatory
cytokines: IL-1β and TNF-α stimulate the growth of early progenitors BFU-E, but suppresses
the growth of the later stages, inducing apoptosis in CFU-E [74]; indirectly as IL-1β and
TNF-α stimulate the production of INF-γ [75], known to mediate erythropoiesis suppres‐
sion.
• accelerated destruction of erythrocytes (as referred above in the uremic toxins section) by
the reticulo-endothelial macrophages activated by the inflammatory state [76];
• reduction of EPO production: in hypoxic conditions, IL-1β and TNF-α increase the expres‐
sion GATA and NF-κB, both inhibitory of the transcriptional factors of EPO gene [77];
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• impaired iron availability for erythropoiesis: transferrin receptors in erythroid and non
erythroid cells can be down-regulated by inflammatory cytokines reducing iron uptake [76];
they can also increase the expression of lactoferrin receptors and reduce the expression of
ferroportin in macrophages, increasing the iron storage in these cells and reducing the iron
availability [76, 78]; inflammation is responsible for the increase of hepcidin expression, a
regulatory peptide in the iron cycling that reduces iron absorption and mobilization.
Recently, it was reported the existence of a soluble form of the EPOR (sEPOR) [79, 80]. Although
this soluble receptor is able to bind to EPO, the role of these circulating sEPOR in humans
remains largely unknown. sEPOR seems to be increased in patients receiving high ESA doses
[79, 80], and the pro-inflammatory cytokines IL-6 and TNF-α can be responsible for this
increment [79]. sEPOR could, therefore, be associated with ESA resistance through the
inhibition of EPO effectiveness.
4.4. Decreased hepcidin excretion
In the last years hepcidin emerged as a key regulator of iron metabolism. Hepcidin is a peptide
(25 aminoacids) produced, mainly, in hepatocytes, although other sites of production have
been described, such as kidney [81], adipose tissue [82], brain [83] and heart [84, 85]. Hepcidin
expression is regulated by the HAMP gene located in the long arm of chromosome 19 [86].
An increase of hepcidin levels leads to a decrease in iron absorption (hepcidin inhibits DMT1
transcription [87] or promotes an ubiquitin-dependent proteasome degradation of DMT1 [88])
and an inhibition of iron release from its storages (macrophages and hepatocytes) as hepcidin
binds to ferroportin (the only known iron exporter in the cells) promoting its internalization
and degradation in lysosomes (Fig. 1) [89, 90].
Hepcidin is increased in HD patients [91, 92], and it is regulated by inflammation [93] and
linked to ESA resistance. Hepcidin correlates with IL-6, the cytokine that stimulate its pro‐
duction [94, 95], and with ferritin reflecting high inflammation and high levels of iron stores
[96]. Some authors point that hepcidin could be a marker of functional iron deficiency [86] and
that ESA therapy can decrease hepcidin levels [72, 96].
The kidney appears to play a role in the excretion of hepcidin, as this peptide is found in urine
[97]. Hepcidin levels are increased in HD patients, and its levels appears to be reduced after
HD procedure, supporting the role of kidneys in the excretion of this peptide [91, 92].
4.5. Secondary hyperparathyroidism
The parathyroid hormone (PTH) is  considered by EUTox Work Group [98]  as a middle
molecule uremic toxin with some biological  effects.  Secondary hyperparathyroidism is  a
condition resulting from the deregulation of calcium and phosphorus homeostasis in the
kidney. It  seems that PTH could be a marker of hyporesponsiveness to ESAs in dialysis
patients [99, 100].
Several mechanisms have been proposed as interference with RBC production as PTH causes
bone marrow fibrosis, has an inhibitory effect on BFU-E and interferes with EPO endogenous
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production [99, 101-103]; interference with RBC survival as PTH increases osmotic fragility of
erythrocytes [102, 103].
4.6. Aluminium toxicity
Although  the  recent  progresses  in  the  dialysis  procedures,  some  patients  present  high
levels  of  aluminium (Al)  [104].  Usually,  high levels  of  Al  cause a microcytic,  hypochro‐
mic or normochromic anemia that is hyporesponsive to ESA therapy, as it interferes with
the enzymes necessary for  the heme synthesis  [67,  105].  The sources for  the increase in
plasma  Al  levels  seems  to  be  the  water  used  for  dialysis  [105],  medications  given  i.v.
[104] and infections [106].
Figure 1. Iron metabolism and hepcidin. The iron is present in the diet as either heme iron (Fe2+) or nonheme iron
(Fe3+). Nonheme iron must first be reduced to Fe2+, by duodenal cytochrome B (DcytB), before it can be transported by
the divalent metal iron transporter 1 (DMT1). Once inside the enterocyte, the newly absorbed iron enters the intracel‐
lular iron pool. If the iron is not required by the body, it is loaded onto the iron storage protein ferritin. Iron required
by the body is transferred across the basolateral membrane by ferroportin (FPN). The export of iron also requires the
ferroxidase hephaestin (HEPH). Heme carrier protein (HCP1) can transport heme; the enzyme heme-oxigenase 1
(HO-1) is required for releasing iron from heme. Hepcidin expression in the liver inhibits iron absorption from the diet
and the release of iron from its storage.
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4.7. Vitamin deficiencies (e.g. folate or vitamin B12 deficiency)
The deficiency of folate or vitamine B12 is not very common in dialysis patients, but as these
nutrients are water soluble and can be easily loss during dialysis, they can become a cause of
ESA resistance, especially in patients with malnutrition. The supplementation of these
nutrients seems to overcome ESA hyporesponsiveness [66, 67].
4.8. Malnutrition
Low body mass index (BMI) and low levels of cholesterol are related to poor outcomes in
dialysis patients, increasing the risk of mortality [107]. This phenomenon, called as “reverse
epidemiology”, is based on the malnutrition-inflammatory complex [108]. These patients
present a decreased nutritional reserve, reducing its capacity to overcome inflammation; they
also present a reduced protein-calorie intake, chronic acidosis and failure of vascular access
[108]. A diminished nutritional status and the enhancement of inflammation could be respon‐
sible for the requirement of higher EPO doses [69, 108].
4.9. Inadequate dialysis
Intensity or adequacy of dialysis (measured by Kt/V) is a factor that can modulate the response
to ESA therapy. Inadequate dialysis is associated with the need for higher ESA doses. Some
studies showed that convective treatments present benefits in ESA response, as compared with
other treatments [109]. High flux HD (HF-HD) and online hemodialfiltration (OL-HDF)
improve the response to ESAs, as compared to low flux HD (LF-HD), probably due to a better
removal of middle and large molecules that impair erythropoiesis [67, 92, 109]. However, some
studies failed to reach to these conclusions [110].
4.10. Angiotensin-converting enzyme inhibitors and angiotensin receptors blockers
These drugs, used for hypertension control, can be associated with ESA hyporesponsiveness
due to its effects on angiotensin II. They can act through several mechanisms, not well
understood, including inhibition of angiotensin-induced EPO release and increased plasma
levels of N-acetyl-serylaspartyl-lysil-proline that impairs the recruitment of pluripotent
hemopoietic stem cells [66, 67].
4.11. Testosterone deficiency
It appears that low testosterone levels may contribute to anemia in men with CKD and to ESA
resistance. Testosterone stimulates erythropoiesis through the production of hematopoietic
growth factors and possible improvement of iron bioavailability [111, 112].
5. Controversies in the treatment of anemia in chronic kidney disease
Since the introduction of ESAs therapy a demand exists to define the better Hb target associated
with lower CV risks. Indeed, recent studies reported increased CV risk and death in patients
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treated with high doses of EPO to achieve higher Hb levels, and this led to the controversy of
what is the cause of these increased risk: higher doses of EPO or higher levels of Hb?
5.1. Clinical trials
The correction of anemia to higher target Hb levels with ESAs in CKD or ESRD patients merits
attention, as it may be associated with increased risk of death or of CV events, namely, stroke,
hypertension, and vascular access thrombosis [6].
Only four studies assessed properly the effect of higher Hb levels on the increased risk of CV
events and/or death.
5.1.1. Normal hematocrit trial (NHT) [113]
This study included patients under HD with congestive heart failure or ischemic heart disease.
They were randomized to one of two groups to receive epoetin alpha, aiming to achieve and
maintain a target hematocrit (Ht) of 42% or 30%. Primary end points were the length of time
to death or for the first nonfatal myocardial infarction (MI). The study was interrupted due to
the increased number of deaths observed in the high-Ht group and that were nearing the
boundary of statistical significance. An increased rate of incidence of vascular access throm‐
bosis was also reported in the high-Ht group. The study failed to reach statistical difference
between the two groups, however, it was concluded that a target Ht of 42% is not recom‐
mended in HD patients.
5.1.2. Cardiovascular risk reduction by early anemia treatment with epoetin beta (CREATE) [53]
This study included pre-dialysis patients in stage 3 or 4 with mild-to-moderate anemia. They
were randomly assigned to normalization of Hb values (13.0-15.0g/dL) or to a partial correction
of anemia (10.5-11.5 g/dL), in order to investigate the effect of Hb correction on complications
from CV causes. The primary endpoint was the time for the first CV event. Secondary objectives
included the investigation of the effects of these treatments on the left ventricular mass index,
the progression of CKD, and the quality of life. They did not find a significant difference in
the risk for a first CV event between the two groups. However, this study reported a higher
incidence of hypertension and headaches, and a higher risk for starting dialysis in the group
aiming normalization of Hb values. But they also reported significant benefits on the quality
of life for the patients with higher Hb targets.
In conclusion, they found that in pre-dialysis patients with mild-to-moderate anemia, the
normalization of Hb levels to 13.0 to 15.0 g/dL did not reduce CV events.
5.1.3. Correction of hemoglobin and outcomes in renal insufficiency (CHOIR) [114]
Non-dialysis patients with CKD were included and the effect of raising Hb concentration with
epoetin alpha to a target Hb value of 13.5 g/dL or 11.3 g/dL was compared. The primary end
point was the time of death, MI, hospitalization for congestive heart failure (excluding renal
replacement therapy), or stroke.
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An increased risk of the primary end point, for the high-Hb group, as compared with the low-
Hb group was found. Death and hospitalization for congestive heart failure accounted for
74.8% of the events. An increased rate of thrombotic events was also reported in the group of
high-Hb. Patients in the high-Hb group had a higher (but not significant) rate of both pro‐
gression to renal replacement therapy and hospitalization for renal replacement therapy. They
did not find any apparent additional benefit in quality of life. In conclusion, they recommended
the use of a target Hb level of 11.0 to 12.0 g/dL rather than a level of 11.0 to 13.0 g/dL, because
of the increased risk, increased costs, and no quality-of-life benefit.
5.1.4. Trial to reduce cardiovascular events with aranesp therapy (TREAT) [115]
In this trial patients with type 2 diabetes mellitus, CKD and anemia were enrolled. Patients
were randomized to receive darbepoetin-alfa (in order to achieve a target Hb of 13.0 g/dL) or
placebo (in this group were prescribed blinded “rescue” darbepoetin for Hb level < 9.0 g/dL).
The primary end point was time to death or hospitalization for myocardial ischemia. A
significantly higher rate of strokes in patients treated with darbepoetin was observed. A higher
rate of both thromboembolism and cancer-related deaths among patients with a history of
cancer in the treatment group was also reported in the treatment group.
Higher targets of Hb levels imply the use of higher ESA doses. Therefore, the increased risk
for adverse CV outcomes could also result from the higher ESAs doses and not only from the
normalization of Hb [116]. In this sense, a trial has been designed to identify the potential
benefits and harms of different fixed doses of ESA. The Clinical Evaluation of the DOSe of
Erythropoietins (C.E. DOSE) trial [117] enrolled HD patients that were randomized 1:1 to 4000
IU/week versus 18000 IU/week of i.v. epoietin alfa or beta, or of any other ESA in equivalent
doses. The primary outcome was death, non fatal stroke, non fatal MI and hospitalization for
CV causes.
Several potential mechanisms for harm with higher Hb targets have been proposed and revised
by Fishbane et al. [118]. The hypothesis is that increased viscosity and hemoconcentration, the
increased BP, the toxic effect of iron and unphysiological doses of ESAs contribute to ESAs
toxicity. The rise in Ht results in a higher viscosity and, consequently, higher risk of thom‐
boembolism. It also favors platelet activation by increasing the interaction between the
endothelial cells and platelets in blood vessels. Hemoconcentration is a phenomenon observed
in these patients after a dialysis session that results from the removal of large amounts of fluids.
5.2. Safety advisories
Considering the results of these studies, in 2007 the FDA launched a safety advisory, recom‐
mending that patients do not exceed the Hb level of 12g/dL [119]. At the same time, the NKF
KDOQI made an update on its guidelines, recommending that the selected Hb target should
generally be in the range of 11.0 to 12.0 g/dL, but should not be greater than 13.0 g/dL [120].
In 2010, the European Best Practice Guidelines Work Group published the recommendation
that “Hb values of 11-12 g/dL should be generally sought in the CKD population without
intentionally exceeding 13 g/dL” [121]. In 2011, the FDA introduced warnings in the ESA label
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giving the recommendations “for more conservative dosing of Erythropoiesis-Stimulating
Agents (ESAs) in patients with chronic kidney disease (CKD) to improve the safe use of these
drugs” [122].
5.3. Hemoglobin variability
In conjugation with the optimal Hb target and ESA dose, there is a study of Hb variability (Hb-
var). It was noted that during the treatment of HD patients with ESAs the level of Hb have a
great fluctuation, that is, the Hb levels tends to rise or fall in a cyclic pattern, that is different
for each patient [123]. However, the impact of this Hb-var is not still elucidated. Some studies
show that there is an association between Hb-var and increase of death [11, 64, 65], especially
if this variability is greater than 1g/dL [11]. The main factor for this variability is ESA dose;
however, other factors have been pointed, as i.v. iron and other biological factors (inflamma‐
tion and nutritional status) [123].
Hb-var represents an important physiological stress, as the ESA treatment involves short,
intermittent burst of plasma EPO availability that do not coincide, either temporally or in
magnitude with its physiological action. Under physiological conditions EPO levels are
maintained in a narrow range, through several mechanisms, in order to support a constant
oxygen supply to the organs. The impact of Hb-var on the organism is not fully understood,
but the myocardium may be one of the most affected organs, as it has to compensate with an
increased output and cardiomyocytes proliferation during the periods of reduced oxygen
availability, that occur when Hb reaches lower levels, before the new ESA administration. This
might result in deregulation of cardiac growth signal, leading to left ventricular dilation and
hypertrophy [11, 123]. The autonomic nervous system can also suffer from this Hb-var;
actually, autonomic dysfunction occurs in other pathological conditions, where Hb-var also
occurs, like sickle cell anemia [11]. Fishane et al. also [123] found that better responders to ESA
tend to have a higher degree of Hb-var.
6. Conclusion
Despite all the technologic advances in HD procedure and medical support, the morbidity and
mortality in CKD patients remains high, particularly in hyporesponsiveness patients to ESAs
therapy. The clinical trials showed that a higher Hb target is associated with increased risk of
cardiovascular complications and death; however, the impact of higher ESAs doses to achieve
higher Hb targets remains unclear. Some evidence points that the pleiotropic effects of ESAs
can contribute to the ESAs toxicity observed with higher doses. Meanwhile, the recommen‐
dations to target Hb to a range of 11 – 12 g/dL, without exceeding the 13g/dL, with the lower
doses of ESAs to accomplish this goal, can reduce the risks associated with higher Hb target
and higher ESAs doses in CKD patients. More studies are needed on this field to evaluate the
impact of the linkage anemia/high sustained ESAs therapeutic doses in CKD that might explain
the high mortality in hyporesponsiveness patients. To accomplish these goals blood, cellular
and tissue studies are need that cannot be performed in humans; therefore, the use of appro‐
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priate animal models could be useful to understand whether the association of moderate
anemia and high sustained therapeutic doses of ESAs in non-responders is beneficial or an
increasing risk; to clarify the underlying mechanisms and, eventually, to propose new
therapeutic strategies to reduce mortality in HD patients.
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